Key Points Pevonedistat targets the NFκB pathway to inhibit growth of MPN and sAML cells. Pevonedistat reduces disease burden in MPN mouse models. Pevonedistat targets malignant cells in myeloproliferative neoplasms in vitro and in vivo via NFκB pathway inhibition Abstract Targeted inhibitors of JAK2 (eg ruxolitinib) often provide symptomatic relief for myeloproliferative neoplasm (MPN) patients, but the malignant clone […]
New Horizons in MPN Treatment, A Review of Therapeutic Options
Abstract Philadelphia-negative myeloproliferative neoplasms (MPN) are aggressive diseases characterized by clonal proliferation of myeloid stem cells. The clonal process leads to excessive red cells production, platelets production, and bone marrow fibrosis. According to the phenotype, MPN can be classified as polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). MPN patients have shortened survival […]
Financial Patient Assistance Programs for MPNs
by Lou Ann Donovan The World Health Organization (WHO) published a revised document in 2008 listing MPNs as a blood cancer to promote the recognition of the genetic characterization of myeloid malignancies. Now, there are numerous organizations providing financial support and assistance with travel to a cancer center, copay and medication assistance, and many programs […]
Being an MPN Patient in COVID-19 Era: The Mytico Study
Introduction: The Coronavirus disease 2019 (COVID-19) pandemic and the resulting social distancing, determined a reduction in access to care and limitations of individual freedom, with a consequent strong impact on quality of life (QoL), anxiety levels and medical management of onco-hematological people. In particular, in the case of patients with chronic myeloproliferative neoplasm (MPN), concern […]
Michael’s MPN Story
by Michael Movsky My MPN journey began at the hematologist’s office on a pleasant March day in 2018, when she confirmed a diagnosis of Essential Thrombocytosis (ET) through various factors, including the detection of the JAK 2 mutation…at which point I was handed an informational booklet on the topic from the Leukemia and Lymphoma Society. […]
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 8
- Next Page »
